-
EP2697196
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2697196
| EP2697196 - PRODRUGS OF INHIBITORS OF PLASMA KALLIKREIN [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 18.12.2015 Database last updated on 22.08.2024 | Most recent event Tooltip | 18.12.2015 | Application deemed to be withdrawn | published on 20.01.2016 [2016/03] | Applicant(s) | For all designated states Activesite Pharmaceuticals, Inc. 187 Magellan Avenue San Francisco, CA 94116 / US | [2014/08] | Inventor(s) | 01 /
SINHA, Sukanto 187 Magellan Avenue San Francisco California 94116 / US | 02 /
CHILCOTE, Tamie Jo 187 Magellan Avenue San Francisco California 94116 / US | 03 /
SURESH, Joghee Raju c/o Syngene International Ltd. Biocon Park, Plot 2 & 3 Bommasandra Industrial Estate - Phase-IV Bommasandra-Jigani Link Road Bangalore 560 099 / IN | 04 /
NARASIMHAN, Sriram c/o Syngene International Ltd. Biocon Park, Plot 2 & 3 Bommasandra Industrial Estate - Phase-IV Bommasandra-Jigani Link Road Bangalore 560 099 / IN | [2014/09] |
| Former [2014/08] | 01 /
SINHA, Sukanto 187 Magellan Avenue San Francisco California 94116 / US | ||
| 02 /
CHILCOTE, Tamie Jo 187 Magellan Avenue San Francisco California 94116 / US | |||
| 03 /
SURESH, Joghee Raju Bangalore Karnataka / IN | |||
| 04 /
NARASIMHAN, Sriram Bangalore Karnataka / IN | Representative(s) | Campbell, Patrick John Henry J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB | [2014/08] | Application number, filing date | 12723771.7 | 12.04.2012 | WO2012US33353 | Priority number, date | US201161517065P | 13.04.2011 Original published format: US 201161517065 P | [2014/08] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2012142308 | Date: | 18.10.2012 | Language: | EN | [2012/42] | Type: | A1 Application with search report | No.: | EP2697196 | Date: | 19.02.2014 | Language: | EN | The application published by WIPO in one of the EPO official languages on 18.10.2012 takes the place of the publication of the European patent application. | [2014/08] | Search report(s) | International search report - published on: | EP | 18.10.2012 | Classification | IPC: | C07D207/34, C07D231/14, A61K31/402, A61K31/415, A61P9/10 | [2014/08] | CPC: |
C07D207/34 (EP,US);
A61P1/00 (EP);
A61P11/06 (EP);
A61P13/12 (EP);
A61P19/02 (EP);
A61P25/00 (EP);
A61P25/16 (EP);
A61P25/28 (EP);
A61P27/02 (EP);
A61P29/00 (EP);
A61P31/00 (EP);
A61P35/00 (EP);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2014/08] | Extension states | BA | 08.11.2013 | ME | 08.11.2013 | Title | German: | PRODRUGS VON PLASMAKALLIKREINHEMMERN | [2014/08] | English: | PRODRUGS OF INHIBITORS OF PLASMA KALLIKREIN | [2014/08] | French: | PROMÉDICAMENTS D'INHIBITEURS DE LA KALLICRÉINE PLASMATIQUE | [2014/08] | Entry into regional phase | 08.11.2013 | National basic fee paid | 08.11.2013 | Designation fee(s) paid | 08.11.2013 | Examination fee paid | Examination procedure | 08.11.2013 | Examination requested [2014/08] | 12.06.2014 | Amendment by applicant (claims and/or description) | 28.08.2014 | Despatch of a communication from the examining division (Time limit: M04) | 07.01.2015 | Reply to a communication from the examining division | 09.03.2015 | Communication of intention to grant the patent | 21.07.2015 | Application deemed to be withdrawn, date of legal effect [2016/03] | 24.08.2015 | Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time [2016/03] | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 28.08.2014 | Fees paid | Renewal fee | 25.03.2014 | Renewal fee patent year 03 | Penalty fee | Additional fee for renewal fee | 30.04.2015 | 04 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [YD]WO2008016883 (ACTIVESITE PHARMACEUTICALS INC [US], et al) [YD] 1-31 * page 1, paragraph 4 - page 3, paragraph 10; claim -; table 1 *; | [Y]WO0214270 (ASTRAZENECA AB [SE], et al) [Y] 1-31 * page 11, line 19 - page 12, line 15; claim - *; | [YP]WO2011075684 (ACTIVESITE PHARMACEUTICALS INC [US], et al) [YP] 1-31 * page 1, paragraph 4; example -; claim - * | [Y] - T. WELLER ET. AL., "Orally Active Fibrinogen Receptor Antagonists. 2. Amidoximes as Prodrugs of Amidines.", JOURNAL OF MEDICINAL CHEMISTRY, (19960701), vol. 39, pages 3139 - 3147, XP002185840 [Y] 1-31 * page 3141 - page 3142; tables 1-3 * DOI: http://dx.doi.org/10.1021/jm9509298 | [Y] - M. UCHIDA ET. AL., "Orally active factor Xa inhibitors. Investigation of a novel series of 3-amidinophenylsulfonamide derivatives using an amidoxime prodrug strategy.", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, (20080709), vol. 18, pages 4682 - 4687, XP023613449 [Y] 1-31 * table 2 * DOI: http://dx.doi.org/10.1016/j.bmcl.2008.07.009 | [Y] - H. KOSHIO ET. AL., "Orally active factor Xa inhibitor: synthesis and biological activity of masked amidines as prodrugs of novel 1,4-diazepane derivatives.", BIOORGANIC AND MEDICINAL CHEMISTRY, (20040819), vol. 12, pages 5415 - 5426, XP002680255 [Y] 1-31 * tables 1-3 * DOI: http://dx.doi.org/10.1016/J.BMC.2004.07.046 | by applicant | WO2008016883 | US7625944 | US2002012680 | US4256108 | US4166452 | US4265874 | US4733655 | US4800882 | US4886062 | US5102417 | WO9112779 | WO9013332 | US5419760 | US5429634 | US2004243225 | US6770729 | WO2009000971 | - SCHOENEGGER K; OBEMDORFER S, EUR J NEURAL., (200907), vol. 16, no. 7, pages 874 - 8 | - PHIPPS, J.A. ET AL., HYPERTENSION, (2009), vol. 53, pages 175 - 181 | - CLERMONT A.C. ET AL., DIABETES, (2011), vol. 60, pages 1590 - 8 | - KISHIMOTO, T.K. ET AL., N. ENGL. J. MED., (2008), vol. 358, pages 2457 - 2467 | - BERGE, S.M. ET AL., "Pharmaceutical Salts", JOURNAL OF PHARMACEUTICAL SCIENCE, (1977), vol. 66, doi:doi:10.1002/jps.2600660104, pages 1 - 19, XP002675560 DOI: http://dx.doi.org/10.1002/jps.2600660104 | - IKEDA, Y. ET AL., CANCER RESEARCH, (2004), vol. 64, pages 5178 - 5185 | - TARASEVICIENE-STEWART, L. ET AL., PEPTIDES, (2005), vol. 26, pages 1292 - 1300 | - ENNIS, S. ET AL., LANCET, (2008), vol. 372, pages 1828 - 1834 | - INDERBITZIN, D. ET AL., EUR. SURG. RES., (2004), vol. 36, pages 142 - 147 | - HORSTICK, G. ET AL., CIRCULATION, (2001), vol. 104, pages 3125 - 3131 | - WILLIAMS, A. ET AL., TRANSFUS. APHER-. SCI., (2003), vol. 29, pages 255 - 258 | - SCHNEIDER, L. ET AL., J ALLERGY CLIN IMMUNOL., (2007), vol. 120, no. 2, pages 416 - 22 | - LEVY, J.H. ET AL., EXPERT OPIN. INVEST. DRUGS, (2006), vol. 15, pages 1077 - 1090 | - BORK, K. ET AL., J. ALLERGY CLIN. IMMUNOL., (2007), vol. 119, pages 1497 - 1503 | - HOFFMCISTCR, H.M., J. CARDIOVASC. PHARMACOL., (1998), vol. 31, pages 764 - 72 | - EWALD, G.A. ET AL., CIRCULATION, (1995), vol. 91, pages 28 - 36 | - HOFFMEISTER, H.M. ET AL., CIRCULATION, (1998), vol. 98, pages 2527 - 33 | - STORINI, C. ET AL., J. PHARM. EXP. THER., (2006), vol. 318, pages 849 - 854 | - DE SIMONI, M.G. ET AL., ANT..1. PATHOL., (2004), vol. 164, pages 1857 - 1863 | - AKITA, N. ET AL., NEUROSURGERY, (2003), vol. 52, pages 395 - 400 | - LIU, J. ET AL., NATMED., (2011), vol. 17, pages 206 - 10 | - ZAUSINGER, S. ET AL., ACTA NEUROCHIR. SUPPL., (2003), vol. 86, pages 205 - 207 | - LUMENTA, D.B. ET AL., BRAIN RES., (2006), vol. 1069, pages 227 - 234 | - DING-ZHOU, L. ET AL., BR. J. PHAMRZACNL., (2003), vol. 139, pages 1539 - 1547 | - WACHTFOGEL, Y.T., BLOOD, (1989), vol. 73, page 468 | - CUGNO, M. ET AL., CHEST, (2006), vol. 120, pages 1776 - 1782 | - CAMPBELL, D.J. ET AL., AM. J. PHYSIOL. REG. LNTEGR. COMP. PHYSIOL, (2001), vol. 281, pages 1059 - 1070 | - MOJCIK, C.F.; LEVY, J.H., ANN THORAC SURG., (200102), vol. 71, no. 2, pages 745 - 54 | - DE LA CADENA, R.A. ET AL., FASEB J., (1995), vol. 9, pages 446 - 452 | - FUJIMORI, Y., AGENTS ACTION, (1993), vol. 39, pages 42 - 48 | - BLAIS, C. JR. ET AL., ARTHRITIS RHEUM., (1997), vol. 40, pages 1327 - 1333 | - STADNICKI, A. ET AL., FASEB J, (1998), vol. 12, no. 3, pages 325 - 33 | - STADNICKI, A., DIG. DIS. SCI., (1996), vol. 41, pages 912 - 920 | - DC LA CADCNA, R.A., FASEB J., (1995), vol. 9, pages 446 - 452 | - SARTOR, R.B. ET AL., GASTROENTEROLOGY, (1996), vol. 110, pages 1467 - 1481 | - ARAI, Y. ET AL., DIG. DIS. SCI., (1999), vol. 44, pages 845 - 851 | - KEITH, J.C. ET AL., ARTHRITIS RES. THERAPY, (2005), vol. 7, pages R769 - R776 | - LIU, D. ET AL., BLOOD, (2005), vol. 105, pages 2350 - 2355 | - PERSSON, K. ET AL., J. EXP. MED., (2000), vol. 192, pages 1415 - 1424 | - ZEERLEDER, S. ET AL., CLIN. DIAGNOST. LAB. IMMUNOL., (2003), vol. 10, pages 529 - 535 | - CALIEZI, C. ET AL., CRIT. CARE MED., (2002), vol. 30, pages 1722 - 8 | - MARX, G. ET AL., INTENSIVE CARE MED., (1999), vol. 25, pages 1017 - 20 | - MARTINEZ-BROTONS, F. ET AL., THROMB. HAEMOST., (1987), vol. 58, pages 709 - 713 | - KALTER, E.S. ET AL., J. INFECT. DIS., (1985), vol. 151, pages 1019 - 1027 | - GAO, B.-B., NATURE MED., (2007), vol. 13, pages 181 - 188 | - KEDZIERSKA, K. ET AL., ARCHIVES MED. RES., (2005), vol. 36, pages 539 - 543 | - CHRISTIE, M. ET AL., THROMB. HAEMOSTAS., (1984), vol. 52, pages 221 - 223 | - LIU, NAT. MED., (2011), vol. 17, pages 206 - 210 | - JAFFA, A.A. ET AL., DIABETES, (2003), vol. 52, pages 1215 - 1221 | - LAWSON, S.R. ET AL., EUR. J. PHARMACOL., (2005), vol. 514, pages 69 - 78 | - LAWSON SR; GABRA BH ET AL., REGUL PEPT., (2005), vol. 124, pages 221 - 4 | - ZUCCOLLO, A. ET AL., CAN. J. PHYSIOL. PHARMACOL., (1996), vol. 74, pages 586 - 589 | US19960746404 |